MARKET

ISR

ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6816
+0.0180
+2.71%
After Hours: 0.6740 -0.0076 -1.12% 19:27 09/17 EDT
OPEN
0.6637
PREV CLOSE
0.6636
HIGH
0.6816
LOW
0.6537
VOLUME
605.90K
TURNOVER
--
52 WEEK HIGH
2.810
52 WEEK LOW
0.3520
MARKET CAP
96.42M
P/E (TTM)
-15.3514
1D
5D
1M
3M
1Y
5Y
BRIEF-Isoray Inc Says On September 9, Isoray Medical Entered Into A Consignment Agreement With Medikorpharma-Ural Llc
reuters.com · 2d ago
Isoray 8-K Shows Co.'s Isoray Medical Unit Entered Consignment Deal With MedikorPharma-Ural For Supply Of Ceisum-131
On September 9, 2021, Isoray Medical, Inc. (“Medical”), a wholly owned subsidiary of Isoray, Inc., entered into a Consignment Agreement (the “Agreement”) with MedikorPharma-Ural LLC, a company
Benzinga · 2d ago
Northland Capital Markets Initiates Coverage On Isoray with Outperform Rating, Announces Price Target of $1.25
Northland Capital Markets analyst Tim Chiang initiates coverage on Isoray (AMEX:ISR) with a Outperform rating and announces Price Target of $1.25.
Benzinga · 3d ago
--Northland Capital Starts IsoRay at Outperform with $1.25 Price Target
MT Newswires · 3d ago
Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 09/09 19:00
Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PTRICHLAND, Wash, Sept. 09, 2021 (GLOBE NEWSWIRE) -- – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options th...
GlobeNewswire · 09/09 12:13
Sidoti Summer Virtual Small-Cap Conference
Presentation Times and Weblinks Released for Approximately 70 Presenting CompaniesWednesday and Thursday, June 23-24, 2021NEW YORK, NY / ACCESSWIRE / June 22, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day ...
ACCESSWIRE · 06/22 20:45
Veritone Announces Device Learning Model for SMA Sunny Central Solar Inverters, Driving Grid Reliability in the Global Transition to Green Energy
DENVER, Jun 22, 2021--Veritone Announces Device Learning Model for SMA Sunny Central Solar Inverters, Driving Grid Reliability in the Global Transition to Green Energy
Business Wire · 06/22 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISR. Analyze the recent business situations of ISORAY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISR stock price target is 1.938 with a high estimate of 3.000 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 2.81%
Shares Outstanding: 141.47M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer/Chief Accounting Officer/Controller/Secretary
Mark Austin
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Vice President/Director of Sales/Director of Marketing
Donna Fort
Vice President - Business Development
Lisa Lauer
Other
William Cavanagh
Other
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
No Data
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Cesium-131 seed is classified as a Class II device.

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.